Insmed Net Worth
Insmed Net Worth Breakdown | INSM |
Insmed Net Worth Analysis
Insmed's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Insmed's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Insmed's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Insmed's net worth analysis. One common approach is to calculate Insmed's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Insmed's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Insmed's net worth. This approach calculates the present value of Insmed's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Insmed's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Insmed's net worth. This involves comparing Insmed's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Insmed's net worth relative to its peers.
Enterprise Value |
|
To determine if Insmed is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Insmed's net worth research are outlined below:
| The company reported the previous year's revenue of 363.71 M. Net Loss for the year was (913.77 M) with profit before overhead, payroll, taxes, and interest of 277.96 M. | |
| Insmed Inc currently holds about 554.87 M in cash with (683.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.62. | |
| Insmed Inc has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: New York Life Investment Management LLC Has 1.23 Million Position in Insmed Incorporated |
Insmed Quarterly Good Will |
|
Insmed uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Insmed Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Insmed's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Insmed Target Price Consensus
Insmed target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Insmed's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 18 | Strong Buy |
Most Insmed analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Insmed stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Insmed Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationInsmed Target Price Projection
Insmed's current and average target prices are 77.55 and 88.14, respectively. The current price of Insmed is the price at which Insmed Inc is currently trading. On the other hand, Insmed's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Insmed Target Price
Know Insmed's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Insmed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Insmed Inc backward and forwards among themselves. Insmed's institutional investor refers to the entity that pools money to purchase Insmed's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Rtw Investments, Llc | 2024-12-31 | 3 M | |
| Ameriprise Financial Inc | 2024-12-31 | 2.9 M | |
| Fidelity International Ltd | 2024-12-31 | 2.6 M | |
| William Blair Investment Management, Llc | 2024-12-31 | 2.4 M | |
| Alliancebernstein L.p. | 2024-12-31 | 2.4 M | |
| Macquarie Group Ltd | 2024-12-31 | 2.3 M | |
| Franklin Resources Inc | 2024-12-31 | 2.2 M | |
| T. Rowe Price Investment Management,inc. | 2024-12-31 | 2 M | |
| Pictet Asset Manangement Sa | 2024-12-31 | 2 M | |
| Vanguard Group Inc | 2024-12-31 | 18.2 M | |
| Blackrock Inc | 2024-12-31 | 16 M |
Follow Insmed's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 13.97 B.Market Cap |
|
Project Insmed's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.52) | |
| Return On Capital Employed | (0.51) | (0.48) | |
| Return On Assets | (0.45) | (0.47) | |
| Return On Equity | (3.20) | (3.04) |
When accessing Insmed's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Insmed's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Insmed's profitability and make more informed investment decisions.
Evaluate Insmed's management efficiency
Insmed Inc has return on total asset (ROA) of (0.2931) % which means that it has lost $0.2931 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.9075) %, meaning that it created substantial loss on money invested by shareholders. Insmed's management efficiency ratios could be used to measure how well Insmed manages its routine affairs as well as how well it operates its assets and liabilities. As of the 5th of March 2025, Return On Tangible Assets is likely to drop to -0.52. In addition to that, Return On Capital Employed is likely to grow to -0.48. At this time, Insmed's Intangible Assets are very stable compared to the past year.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.74 | 1.65 | |
| Tangible Book Value Per Share | 0.55 | 0.52 | |
| Enterprise Value Over EBITDA | (13.21) | (12.55) | |
| Price Book Value Ratio | 39.69 | 41.67 | |
| Enterprise Value Multiple | (13.21) | (12.55) | |
| Price Fair Value | 39.69 | 41.67 | |
| Enterprise Value | 9.7 B | 10.2 B |
Leadership at Insmed emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Enterprise Value Revenue 37.2023 | Revenue | Quarterly Revenue Growth 0.248 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Insmed insiders, such as employees or executives, is commonly permitted as long as it does not rely on Insmed's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Insmed insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Insmed Corporate Filings
F4 | 27th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 24th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10K | 20th of February 2025 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify |
Insmed Earnings Estimation Breakdown
The calculation of Insmed's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Insmed is estimated to be -1.2 with the future projection ranging from a low of -1.5 to a high of -1.0082. Please be aware that this consensus of annual earnings estimates for Insmed Inc is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.5 Lowest | Expected EPS | -1.01 Highest |
Insmed Earnings Projection Consensus
Suppose the current estimates of Insmed's value are higher than the current market price of the Insmed stock. In this case, investors may conclude that Insmed is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Insmed's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 18 | 85.58% | -1.32 | -1.2 | -5.57 |
Insmed Earnings per Share Projection vs Actual
Actual Earning per Share of Insmed refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Insmed Inc predict the company's earnings will be in the future. The higher the earnings per share of Insmed, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Insmed Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Insmed, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Insmed should always be considered in relation to other companies to make a more educated investment decision.Insmed Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Insmed's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-20 | 2024-12-31 | -1.23 | -1.32 | -0.09 | 7 | ||
2024-10-31 | 2024-09-30 | -1.22 | -1.27 | -0.05 | 4 | ||
2024-08-08 | 2024-06-30 | -1.27 | -1.94 | -0.67 | 52 | ||
2024-05-09 | 2024-03-31 | -1.23 | -1.06 | 0.17 | 13 | ||
2024-02-22 | 2023-12-31 | -1.15 | -1.28 | -0.13 | 11 | ||
2023-10-26 | 2023-09-30 | -1.13 | -1.11 | 0.02 | 1 | ||
2023-08-03 | 2023-06-30 | -1.13 | -1.78 | -0.65 | 57 | ||
2023-05-04 | 2023-03-31 | -1.11 | -1.17 | -0.06 | 5 | ||
2023-02-23 | 2022-12-31 | -1.04 | -1.21 | -0.17 | 16 | ||
2022-10-27 | 2022-09-30 | -0.89 | -1.09 | -0.2 | 22 | ||
2022-08-04 | 2022-06-30 | -0.89 | -0.8 | 0.09 | 10 | ||
2022-05-05 | 2022-03-31 | -0.88 | -0.8 | 0.08 | 9 | ||
2022-02-17 | 2021-12-31 | -0.9 | -0.95 | -0.05 | 5 | ||
2021-10-28 | 2021-09-30 | -0.86 | -0.89 | -0.03 | 3 | ||
2021-08-05 | 2021-06-30 | -0.85 | -0.91 | -0.06 | 7 | ||
2021-05-06 | 2021-03-31 | -0.89 | -0.89 | 0.0 | 0 | ||
2021-02-25 | 2020-12-31 | -0.7 | -1.0 | -0.3 | 42 | ||
2020-10-29 | 2020-09-30 | -0.61 | -0.63 | -0.02 | 3 | ||
2020-08-06 | 2020-06-30 | -0.63 | -0.64 | -0.01 | 1 | ||
2020-04-30 | 2020-03-31 | -0.71 | -0.74 | -0.03 | 4 | ||
2020-02-25 | 2019-12-31 | -0.58 | -0.59 | -0.01 | 1 | ||
2019-10-30 | 2019-09-30 | -0.67 | -0.68 | -0.01 | 1 | ||
2019-08-01 | 2019-06-30 | -0.86 | -0.81 | 0.05 | 5 | ||
2019-05-07 | 2019-03-31 | -0.95 | -0.96 | -0.01 | 1 | ||
2019-02-22 | 2018-12-31 | -1.05 | -1.19 | -0.14 | 13 | ||
2018-10-30 | 2018-09-30 | -1.06 | -1.14 | -0.08 | 7 | ||
2018-08-02 | 2018-06-30 | -1.08 | -1.0 | 0.08 | 7 | ||
2018-05-02 | 2018-03-31 | -0.98 | -0.89 | 0.09 | 9 | ||
2018-02-23 | 2017-12-31 | -0.64 | -0.85 | -0.21 | 32 | ||
2017-11-02 | 2017-09-30 | -0.69 | -0.69 | 0.0 | 0 | ||
2017-08-03 | 2017-06-30 | -0.63 | -0.72 | -0.09 | 14 | ||
2017-05-03 | 2017-03-31 | -0.6 | -0.6 | 0.0 | 0 | ||
2017-02-23 | 2016-12-31 | -0.89 | -1.1 | -0.21 | 23 | ||
2016-11-03 | 2016-09-30 | -0.59 | -0.61 | -0.02 | 3 | ||
2016-08-04 | 2016-06-30 | -0.56 | -0.59 | -0.03 | 5 | ||
2016-05-05 | 2016-03-31 | -0.56 | -0.54 | 0.02 | 3 | ||
2016-02-25 | 2015-12-31 | -0.49 | -0.51 | -0.02 | 4 | ||
2015-11-06 | 2015-09-30 | -0.47 | -0.5 | -0.03 | 6 | ||
2015-08-06 | 2015-06-30 | -0.48 | -0.47 | 0.01 | 2 | ||
2015-05-07 | 2015-03-31 | -0.5 | -0.55 | -0.05 | 10 | ||
2015-02-27 | 2014-12-31 | -0.56 | -0.36 | 0.2 | 35 | ||
2014-11-06 | 2014-09-30 | -0.46 | -0.54 | -0.08 | 17 | ||
2014-08-06 | 2014-06-30 | -0.46 | -0.59 | -0.13 | 28 | ||
2014-05-08 | 2014-03-31 | -0.41 | -0.36 | 0.05 | 12 | ||
2014-03-06 | 2013-12-31 | -0.45 | -0.41 | 0.04 | 8 | ||
2013-11-05 | 2013-09-30 | -0.41 | -0.46 | -0.05 | 12 | ||
2013-08-06 | 2013-06-30 | -0.32 | -0.28 | 0.04 | 12 | ||
2013-05-07 | 2013-03-31 | -0.46 | -0.43 | 0.03 | 6 | ||
2013-03-18 | 2012-12-31 | -0.32 | -0.49 | -0.17 | 53 | ||
2012-11-07 | 2012-09-30 | -0.42 | -0.38 | 0.04 | 9 | ||
2012-08-07 | 2012-06-30 | -0.33 | -0.39 | -0.06 | 18 | ||
2012-05-08 | 2012-03-31 | -0.38 | -0.28 | 0.1 | 26 | ||
2012-03-13 | 2011-12-31 | -0.38 | -0.3 | 0.08 | 21 | ||
2011-11-08 | 2011-09-30 | -0.28 | -0.34 | -0.06 | 21 | ||
2011-08-08 | 2011-06-30 | -0.33 | -0.4 | -0.07 | 21 | ||
2011-05-11 | 2011-03-31 | -0.32 | -0.85 | -0.53 | 165 | ||
2011-03-10 | 2010-12-31 | -0.1 | -0.42 | -0.32 | 320 | ||
2008-03-04 | 2007-12-31 | -0.3 | -0.3 | 0.0 | 0 | ||
2007-11-08 | 2007-09-30 | -0.4 | -0.3 | 0.1 | 25 | ||
2007-08-02 | 2007-06-30 | -0.5 | -0.2 | 0.3 | 60 | ||
2007-05-10 | 2007-03-31 | -0.75 | -1.0 | -0.25 | 33 | ||
2007-03-15 | 2006-12-31 | -1.25 | -2.1 | -0.85 | 68 | ||
2006-11-03 | 2006-09-30 | -1.05 | -1.2 | -0.15 | 14 | ||
2006-08-08 | 2006-06-30 | -1.6 | -0.9 | 0.7 | 43 | ||
2006-05-08 | 2006-03-31 | -1.3 | -1.7 | -0.4 | 30 | ||
2006-03-02 | 2005-12-31 | -2.1 | -2.7 | -0.6 | 28 | ||
2005-11-03 | 2005-09-30 | -2.1 | -2.9 | -0.8 | 38 | ||
2005-08-08 | 2005-06-30 | -2 | -1.9 | 0.1 | 5 | ||
2005-05-10 | 2005-03-31 | -1.2 | -1.3 | -0.1 | 8 | ||
2004-11-08 | 2004-09-30 | -1.4 | -2.0 | -0.6 | 42 | ||
2004-07-28 | 2004-06-30 | -3.1 | -2.3 | 0.8 | 25 | ||
2004-05-05 | 2004-03-31 | -1 | -1.2 | -0.2 | 20 | ||
2004-02-11 | 2003-12-31 | -0.8 | -0.6 | 0.2 | 25 | ||
2002-01-30 | 2001-12-31 | -3 | -3.0 | 0.0 | 0 | ||
2001-11-01 | 2001-09-30 | -2.93 | -2.5 | 0.43 | 14 | ||
2001-08-02 | 2001-06-30 | -3.25 | -2.7 | 0.55 | 16 | ||
2001-02-01 | 2000-12-31 | -4.45 | -2.6 | 1.85 | 41 |
Insmed Corporate Management
| Mandy Fahey | Executive Communications | Profile | |
| Sara MBA | Chief Officer | Profile | |
| Nicole MBA | Chief Officer | Profile | |
| John Wise | Head VP | Profile | |
| Eleanor Barisser | Associate Relations | Profile | |
| MD MBA | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Insmed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insmed. If investors know Insmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insmed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.57) | Revenue Per Share | Quarterly Revenue Growth 0.248 | Return On Assets | Return On Equity |
The market value of Insmed Inc is measured differently than its book value, which is the value of Insmed that is recorded on the company's balance sheet. Investors also form their own opinion of Insmed's value that differs from its market value or its book value, called intrinsic value, which is Insmed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insmed's market value can be influenced by many factors that don't directly affect Insmed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insmed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insmed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insmed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.